| Ticker | EQRX |
|---|---|
| ISIN | US26886C1071 |
| Sector | Atención sanitaria |
| Mercado | NASDAQ |
EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); and Sugemalimab, an anti-programmed death-ligand 1 antibody for the treatment of Stage III and Stage IV...
El precio actual de EQRx, Inc. (EQRX) es de 2,34 , con una variación del -2,09%.
EQRx, Inc. opera en el sector Healthcare, industria Biotechnology.